Nov. 11, 2013
/PRNewswire/ -- Block & Leviton LLP (
-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of ViroPharma Inc. ("ViroPharma" or the "Company") (NASDAQ: VPHM) concerning the proposed acquisition of the Company by U.K.-based company, Shire PLC ("Shire"), in a transaction valued at approximately
. Under the terms of the transaction, Shire will acquire each ViroPharma share for
, representing a paltry premium of 27% to ViroPharma's closing share price on
Friday, November 8
The transaction was announced less than two weeks after ViroPharma announced highly positive third quarter 2013 financial results, which management described as an "extremely strong period of growth and positive momentum across our entire organization." At that time, the Company also raised its North American net sales guidance to between
$395 and $405 million
ViroPharma's share price has been spiking over the last year - trading between
per share on
December 31, 2012
and hitting a high of
, 2013. Indeed, in
, the Company's share price rose nearly 30%. The so-called premium appears to significantly undervalue the Company, especially considering that several companies, including Sanofi, were apparently interested in ViroPharma, which makes Cinryze for the treatment of immune disorder hereditary angioedema. Treatments for such rare disorders can command huge prices, running into hundreds of thousands of dollars a year per patient.
Block & Leviton's investigation seeks to determine, among other things, whether ViroPharma's Directors breached their fiduciary duties by failing to maximize shareholder value in the proposed acquisition by Shire and the fairness by which the ViroPharma's Directors considered and approved the transaction.